Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing-Reference-Cited by-同舟云学术

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

Published:2014-02-02 Issue:3 Volume:46 Page:225-233
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Gerlinger Marco,Horswell Stuart,Larkin James,Rowan Andrew J,Salm Max P,Varela Ignacio,Fisher Rosalie,McGranahan Nicholas,Matthews Nicholas,Santos Claudio R,Martinez Pierre,Phillimore Benjamin,Begum Sharmin,Rabinowitz Adam,Spencer-Dene Bradley,Gulati Sakshi,Bates Paul A,Stamp Gordon,Pickering Lisa,Gore Martin,Nicol David L,Hazell Steven,Futreal P Andrew,Stewart Aengus,Swanton Charles

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.2891.pdf

Reference43 articles.

1. Kern, S.E. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 72, 6097–6101 (2012).

2. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).

3. Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356–361 (2011).

4. Sottoriva, A. et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 110, 4009–4014 (2013).

5. Thirlwell, C. et al. Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology 138, 1441–1454 (2010).

Cited by 1070 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING;2024-09-06

2. Large-scale analysis of whole genome sequencing data from formalin-fixed paraffin-embedded cancer specimens demonstrates preservation of clinical utility;Nature Communications;2024-09-04

3. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer;European Journal of Cancer;2024-09

4. Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review;Medicine;2024-07-26

5. Epigenetic heterogeneity hotspots in human liver disease progression;Hepatology;2024-07-19